Latest Therapeutics News

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

Argenica Therapeutics reports encouraging functional improvements in stroke patients treated with ARG-007, setting the stage for a targeted Phase 2b trial focused on patient-centered outcomes.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

INOVIQ Limited has raised $11.5 million through a $9.5 million placement and a $2 million share purchase plan to accelerate the development and commercialisation of its EXO-OC ovarian cancer test and exosome therapeutic program.